Inhibitor-protected penicillins for bacterial respiratory infections in outpatient pediatric practice
https://doi.org/10.21518/2079-701X-2017-1-136-139
Abstract
More than half a century ago, clinicians first encountered real difficulties in the treatment of infectious diseases due to the development and subsequent spread of pathogens with antimicrobial resistance (AMP). Since then, medical science has been constantly searching for a solution to the problem of ineffective antibacterial therapy (ABT) against a background of rapidly changing sensitivity of microorganisms to antibiotics. One of the medications which could compromise the most common mechanisms of pathogenic resistance is amoxicillin in combination with clavulanic acid. Despite its long-term use, the drug is becoming increasingly relevant for ABT of respiratory bacterial infections today, justifying the trust of doctors and patients with its long history of effective and safe use. The review tells about indications for amoxicillin/clavulanic acid with regard to the most widespread pediatric infections of the upper and lower respiratory tract and the ENT organs in outpatient settings.
About the Authors
A. V. Golub
Research Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Russia’s Ministry of Health
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
R. S. Kozlov
Research Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Russia’s Ministry of Health
Russian Federation
MD, Prof
Russian Federation
MD, Prof
References
1. Feigin RD, Cherry J.D., Demmler G.J et al. Textbook of pediatric infectious diseases. 5th ed. Philadelphia, 2004, 210-310.
2. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. Практическое руководство по антиинфекционной химиотерапии. М.: Боргес, 2007; 464.
3. Rolinson G.N. Forty years of β-lactam research. JAC 1998; 41: 589-603.
4. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность S. pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. Микробиол. Антимикроб. Химиотер. 2006; 8: 33-47.
5. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность S. pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. Микробиол. Антимикроб. Химиотер. 2005; 7: 154-166.
6. Kozlov R.S., Sivaja O.V. Antimicrobial resistance of clinical H. influenzae in Russia: results of prospective multicenter study (PEhASus). Proceedings of the 8th European Congress of Chemotherapy and Infection. Budapest, Hungary; 26-28 October, 2006; 280.
7. Научный отчет о результатах исследования эпидемиологии антимикробной резистентности клинических штаммов S. pneumoniae в России (по данным многоцентрового исследования ПеГАС- III). Смоленск, 2010.
8. Научны й отчет о многоцентровом исследовании антимикробной резистентности клинических штаммов пневмококков, гемофил и группы А стрептококков (ПеГАс-IV). Смоленск, 2014.
9. Баранова А.А., Страчунского Л.С. Практические рекомендации по применению антибиотиков у детей в амбулаторной практике. МЗ РФ. М., 2006; 42.
10. Berthe-Auce jo A., Girard D., Lorrot M., et al. Evaluation of frequency of paediatric oral liquid medication dosing errors by caregivers: amoxicillin and josamycin. Arch Dis Child 2016; 101: 359-64.
11. Albury hi M.M., Siaf A.A., Noman M.A. Stability study of six brands of amoxicillin trihydrate and clavulanic acid oral suspension present in Yemen markets. J Chem Pharm Res 2013; 5: 293-6.
12. McInty re A.R., Lipman N.S. Amoxicillin–clavulanic acid and trimethoprim–sulfamethoxazole in rodent feed and water: effects of compounding on antibiotic stability. J Am Assoc Lab Anim Sci 2007; 46: 26-32.
13. Bersane tti P.A., Almeidab R. M.R.G., Barboza M. et al. Kinetic studies on clavulanic acid degradation. Biochemical Engineering Journal 2005; 23: 31-36.
14. Santos F.C., Pereira J.F.B., Haga R.B. et al. Stability of clavulanic acid under variable pH, ionic strength and temperature conditions. A new kinetic approach. Biochemical Engineering Journal. 2009; 45: 89-93.
15. Dispersible Tablets. Available at: http://www. unicef.org/supply/index_53571.html
16. Козлов Р.С., Голуб А.В. Стратегия использования антимикробных препаратов как попытка ренессанса антибиотиков. Клин. Микробиол. Антимикроб. Химиотер. 2011; 13: 322-34.
Review
For citations:
Golub AV, Kozlov RS. Inhibitor-protected penicillins for bacterial respiratory infections in outpatient pediatric practice. Meditsinskiy sovet = Medical Council. 2017;(1):136-139. (In Russ.) https://doi.org/10.21518/2079-701X-2017-1-136-139
Views:
1177
Email this article 